Symposium on industrial production technology of cell therapy
Professor of southern medical university | Nanjing university, PhD
Professor Kui Cheng obtained his PhD in Nanjing University in 2011. After that, he had 3 years post-doc training in University of Colorado Boulder (USA). Then he moved back to China and employed as a Research associated Professor in Tsinghua University. After 1.5 years, he joined in Southern Medical University and work until today. His research interesting is targeting immune proteins and developing new small molecule modulators for anti-inflammatory and tumor immunotherapy. Until today, he published a lot of high impact research article, including Sci. Adv., J. Am. Chem. Soc., Angew. Chem. Int. Edit. et al. And also applied 4 PCT Patent, including two authorized.
Toll-like receptor2 modulators and tumor immunity
The ability of toll-like receptors (TLRs) to activate both immune systems has made them desirable targets both for vaccine adjuvants and/or cancer treatment. For example, the modified TLR4 agonist, monophosphoryl lipid A (MPLA), is used as an adjuvant in the FDA approved adult cervical cancer vaccine. Imiquimod (INN) is a FDA approved drug which functions through TLR7 and used for the treatment of genital warts, superficial basal cell carcinoma and actinic keratosis. Recently, a TLR2 agonist, Polysaccharide krestin (PSK), extracted from mushroom is being tested in a clinical phase II trial now for the treatment of breast cancer. Accumulated evidences have proven that TLR2 agonists could be used directly, or as structurally modified forms in cancer treatment, suggesting that TLR2 agonists can be potential effective enhancers for cancer immunotherapies. In this talk, i will give an introduction for the TLR2 agonist discovery and their role in tumor immune cancer treatment
Shanghai Jiaotong University | Associate Professor
Dr. Chen joined the Institute of Micro-Nano Science and Technology of Shanghai Jiaotong University in 2006, his research mainly focuses on MEMS, biochemistry, molecular biology, and biological micro-systems. He has deep understanding of the BioMEMS research trends, and has strong practical experience. . He has published more than 20 related research papers, applied 5 invention patents, and granted 3 invention patents. He is the principle investigator of Shanghai Science and Technology Commission project, the Natural Science Fund, the National Defense Key Laboratory Fund Project, and participated in the research work of 863 and 973 related topics.
Speech title: on microfluidic cell sorting technology
Microchips that perform single cell capture, array, and identification have become powerful tools for single cell studies, which can reveal precise underlying mechanisms among bulk cell populations. However, current single cell capture and on-chip immunostaining methods consume more time and reagent than desired. In this seminar, I am going to present several approaches that our group has been working on, including magnetic based microfluidic chip, whalebone-like microfluidic chip and parsortix-like
microfluidic chip for cell separation and arraying, a RC-like fluidic circuit
for fast cell staining.
Dai xiaobing, CEO of Etta Biotech Co., Ltd., has been awarded the “Gusu Entrepreneurship and Innovation Leading Talent”. He graduated from the university of uppsala, Sweden and the Chinese academy of sciences, owning a dual degree in biology and systematics.
His rich R&D and marketing experience accumulated for many years in Mycronic AB in Sweden which is one of the well-known companies in the international electronics industry, makes Dr Dai having the interdisciplinary and cross-industry knowledge base of biology and semiconductor electronic, and comprehensive management experience of R&D, production management and marketing.
Dr Dai has a deep understanding of the biology and electronics industry, and gives an in-depth insight into domestic and international business situations. Hence, his experience in R&D and industrialization will help to push the copmpany into domestic and international markets rapidly. As the inventor, he has applied for 26 patents, including 12 patents, 10 utility models and 4 design patents.
Dr Dai runs the development and operation of products. And, in addition to technological innovation and product innovation, he has promoted the innovation of industrialization of the company.
CEO Jiangsu Jimbio Technology Co. Ltd | Ph.D
2014.3-now, CEO of Jiangsu Jimbio Technology Co. Ltd,
2010.8-2014.3: research associate, Microfluidic and and Lab-on-a-chip lab. Unviersity of Waterloo, Canada
2007.1-2008.4; Visiting Scholar in the microfluidic technology in the Mechanical Engineering of Vanderbilt University. USA
2004-2007; Ph.D Study, Biomedical Engineering Chongqing University, China
Microfluidic Bio-Sensors, Optical Bio-Sensors, Lab-on-a-Chip Technology
Report Subject: Study of Cellular impedance in Microfluidics